Related Experiment Videos
Hydromorphone for cancer pain
Yan J Bao1, Wei Hou, Xiang Y Kong
1Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Beijing, Xicheng District, China, 100053.
The Cochrane Database of Systematic Reviews
|October 12, 2016
Summary
Hydromorphone demonstrated similar pain relief efficacy compared to other opioids for cancer pain. However, the overall evidence quality was very low, necessitating further research for definitive conclusions.
Area of Science:
- Oncology
- Pain Management
- Pharmacology
Background:
- Cancer pain is a prevalent and distressing symptom, significantly impacting patients' quality of life.
- Approximately 15% of cancer patients do not achieve adequate pain relief with conventional treatments.
- Uncontrolled cancer pain can lead to severe physical and psychological distress.
Purpose of the Study:
- To evaluate the analgesic effectiveness of hydromorphone in managing cancer pain.
- To assess the incidence and severity of adverse events associated with hydromorphone use.
- To compare hydromorphone's efficacy against placebo or other active pain medications.
Main Methods:
- Conducted a systematic search of multiple databases up to April 2016.
- Included randomized controlled trials (RCTs) comparing hydromorphone with placebo or other analgesics for cancer pain.
- Analyzed participant-reported pain intensity using visual analogue scales (VAS) and the Brief Pain Inventory (BPI).
Main Results:
- Four studies with 604 adult participants were included, comparing hydromorphone to oxycodone or morphine.
- Hydromorphone showed similar pain intensity reduction compared to oxycodone and morphine, with participants achieving no worse than mild pain.
- Adverse events were generally comparable between groups, with no significant differences noted for typical opioid side effects or other reported events.
Conclusions:
- Hydromorphone exhibits comparable analgesic efficacy to other opioids like oxycodone and morphine for cancer pain.
- The overall quality of evidence is very low, primarily due to risk of bias, imprecision, and potential publication bias.
- Further research with larger sample sizes and comprehensive outcome data is recommended to establish hydromorphone's role in cancer pain management.